ReviewGene therapy2006
Therapeutic short hairpin RNA expression in the liver: viral targets and vectors.
Review in Gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Delivery of Anti-IFNAR1 shRNA to Hepatic Cells Decreases IFNAR1 Gene Expression and Improves Adenoviral Transduction and Transgene Expression.Molecular biotechnology · 2022Article
- Non-coding RNA therapeutics for cardiac regeneration.Cardiovascular research · 2021Review
- MicroRNA‑802 increases hepatic oxidative stress and induces insulin resistance in high‑fat fed mice.Molecular medicine reports · 2019Article
- Profiling the Mismatch Tolerance of Argonaute 2 through Deep Sequencing of Sliced Polymorphic Viral RNAs.Molecular therapy. Nucleic acids · 2017Article
- AAV Gene Therapy for Alcoholism: Inhibition of Mitochondrial Aldehyde Dehydrogenase Enzyme Expression in Hepatoma Cells.Human gene therapy · 2017Article
- Somatic genome editing with CRISPR/Cas9 generates and corrects a metabolic disease.Scientific reports · 2017Article
- TALEN/CRISPR-mediated engineering of a promoterless anti-viral RNAi hairpin into an endogenous miRNA locus.Nucleic acids research · 2017Article
- Adenovirus vectors lacking virus-associated RNA expression enhance shRNA activity to suppress hepatitis C virus replication.Scientific reports · 2013Article
- Vector and helper genome rearrangements occur during production of helper-dependent adenoviral vectors.Human gene therapy methods · 2013Article
- The liver as a target organ for gene therapy: state of the art, challenges, and future perspectives.Pharmaceuticals (Basel, Switzerland) · 2012Article
- In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Retracted: Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Illuminating the gateway of gene silencing: perspective of RNA interference technology in clinical therapeutics.Molecular biotechnology · 2012Review
- Adenovirus delivered short hairpin RNA targeting a conserved site in the 5' non-translated region inhibits all four serotypes of dengue viruses.PLoS neglected tropical diseases · 2012Article
- Potential Use of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for siRNA.Pharmaceuticals (Basel, Switzerland) · 2011Article
- Constitutive expression of short hairpin RNA in vivo triggers buildup of mature hairpin molecules.Human gene therapy · 2011Article
- Effects of HBV Genetic Variability on RNAi Strategies.Hepatitis research and treatment · 2011Article
- A Potential of microRNAs for High-Content Screening.Journal of nucleic acids · 2011Article
- Selective gene silencing by viral delivery of short hairpin RNA.Virology journal · 2010Review
- Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone.Virology journal · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over 500 million people worldwide are infected with one or more different and unrelated types of human hepatitis virus. Such individuals are at a high risk of developing acute or chronic hepatic disease, and ultimately dying from sequelae. Although a vaccine is available for hepatitis A and B virus, treatment options for chronically infected patients are limited, and particularly ineffective in case of hepatitis C virus (HCV) infection. A promising new avenue currently being explored is to harness the power of RNA interference for development of an antiviral therapy. The timing to pursue this particular approach is excellent, with the first in vivo animal models for HCV infection becoming available, and the technology for liver-specific expression of short hairpin RNAs advancing at a rapid pace. Here, we critically review these important current developments, and discuss the next steps to bring this novel approach into the clinics.
Indexed as
Identifiers
16453009What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.